Pharmaceuticals

Short-Acting B2 Agonists Market Developments Shaping Growth Across The Forecast Period

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Short-Acting B2 Agonists Market Between 2026 And 2030?

The short-acting b2 agonists market size has shown consistent expansion over recent years. It is forecast to increase from $4.4 billion in 2025 to $4.58 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.1%. This historical growth can be attributed to several factors including a high prevalence of asthma, the necessity for emergency respiratory care, the demand for fast-acting bronchodilators, established hospital-based treatment protocols, and the widespread availability of generic drugs.

The short-acting b2 agonists market size is poised for consistent expansion in the coming years. It is projected to reach $5.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.2%. This anticipated growth during the forecast period stems from factors such as increasing air pollution, a greater burden of urban respiratory diseases, the rise in home inhaler utilization, an increase in pediatric asthma cases, and the expansion of outpatient respiratory care. Key trends expected within the forecast timeframe encompass the sustained role of these medications as first-line rescue treatments, a growing prevalence of asthma and COPD, a preference for inhalation-based delivery methods, the expansion of homecare respiratory treatment options, and the increasing availability of generic SABA products.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24396&type=smp

What Key Drivers Are Fueling The Growth Of The Short-Acting B2 Agonists Market?

The growing occurrence of chronic obstructive pulmonary disease (COPD) is anticipated to drive expansion in the short-acting B2 agonists market in the future. COPD is a persistent lung condition characterized by impaired airflow and breathing challenges, primarily resulting from extended exposure to hazardous gases or tobacco smoke. The escalation of COPD cases stems from greater exposure to air pollution, given that prolonged inhalation of contaminants such as particulate matter and toxic gases damages lung tissue and hastens the disease’s progression. Short-acting ß2-agonists (SABAs) offer rapid relief from COPD symptoms such as breathlessness by relaxing airway muscles. These serve as emergency treatments during acute exacerbations rather than for ongoing management. For example, a research study from JAMA Network Open, an American Medical Association medical journal, indicated in December 2023 that the global incidence of chronic obstructive pulmonary disease (COPD) is projected to reach approximately 600 million by 2050 globally, signifying a 23% rise in its prevalence. Consequently, the rising prevalence of chronic obstructive pulmonary disease is set to enhance the expansion of the short-acting B2 agonists market.

Which Segment Categories Are Included In The Short-Acting B2 Agonists Market Segment Analysis?

The short-acting b2 agonists market covered in this report is segmented –

1) By Type: Albuterol, Levalbuterol, Metaproterenol, Other Types

2) By Indication: Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm

3) By Administration Route: Inhalation, Oral, Injection

4) By End User: Hospitals, Clinics, Home Healthcare Settings

Subsegments:

1) By Albuterol: Inhalers, Nebulizers, Tablets, Syrups

2) By Levalbuterol: Inhalers, Nebulizers, Oral Solutions

3) By Metaproterenol: Inhalers, Syrups

4) By Other Types: Terbutaline, Pirbuterol, Salbutamol

What Trends Are Shaping The Future Of The Short-Acting B2 Agonists Market?

Leading companies in the short-acting B2 agonists market are concentrating on developing technologically advanced products, such as pressurized metered-dose inhalers (pMDI), to effectively manage acute symptoms. Pressurized metered-dose inhalers (pMDIs) are handheld devices that deliver a specific dose of medication to the lungs in aerosol form using a propellant-driven spray, commonly used for treating respiratory conditions like asthma and COPD. For instance, in January 2023, AstraZeneca, a UK-based pharmaceutical and biotechnology company, announced the US Food and Drug Administration (FDA) approval for Airsupra (albuterol/budesonide). Airsupra is a first-in-class pressurized metered-dose inhaler (pMDI) that combines two active ingredients in a fixed-dose formulation. It contains albuterol, a short-acting beta2-agonist (SABA), for rapid bronchodilation, and budesonide, an inhaled corticosteroid (ICS), to reduce inflammation. This unique combination is approved in the US for the as-needed treatment and prevention of bronchoconstriction in adults with asthma. Additionally, it helps reduce the risk of exacerbations, providing a comprehensive approach to asthma management.

Who Are The Active Companies Shaping The Short-Acting B2 Agonists Market?

Major companies operating in the short-acting b2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.

Get The Full Short-Acting B2 Agonists Market Report:

https://www.thebusinessresearchcompany.com/report/short-acting-b2-agonists-global-market-report

Which Region Has The Greatest Market Share In The Short-Acting B2 Agonists Market?

North America was the largest region in the short-acting B2 agonists market in 2025. The regions covered in the short-acting b2 agonists market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Short-Acting B2 Agonists Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/short-acting-b2-agonists-global-market-report

Browse Through More Reports Similar to the Global Short-Acting B2 Agonists Market 2026, By The Business Research Company

Dopamine Agonists Market Report 2026

https://www.thebusinessresearchcompany.com/report/dopamine-agonists-global-market-report

Muscarinic Acetylcholine Receptor Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscarinic-acetylcholine-receptor-global-market-report

Glp 1 Receptor Agonist Market Report 2026

https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795